In Nexium Case, FDA Pre-Emption Wins; 3rd Circuit Rules For AstraZeneca
This article was originally published in The Tan Sheet
Executive Summary
An appellate court threw out a false advertising suit against AstraZeneca, concluding that since the company's ads complied with FDA-approved labeling, they were not subject to state consumer fraud laws